PE20091693A1 - Antagonista del receptor 2 activado con proteasa - Google Patents
Antagonista del receptor 2 activado con proteasaInfo
- Publication number
- PE20091693A1 PE20091693A1 PE2009000397A PE2009000397A PE20091693A1 PE 20091693 A1 PE20091693 A1 PE 20091693A1 PE 2009000397 A PE2009000397 A PE 2009000397A PE 2009000397 A PE2009000397 A PE 2009000397A PE 20091693 A1 PE20091693 A1 PE 20091693A1
- Authority
- PE
- Peru
- Prior art keywords
- antagonist
- protease
- par2
- activated receptor
- antibody
- Prior art date
Links
- 229940118430 Protease-activated receptor-2 antagonist Drugs 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 abstract 1
- 208000006820 Arthralgia Diseases 0.000 abstract 1
- 208000010392 Bone Fractures Diseases 0.000 abstract 1
- 206010058019 Cancer Pain Diseases 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 206010017076 Fracture Diseases 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 101000603877 Homo sapiens Nuclear receptor subfamily 1 group I member 2 Proteins 0.000 abstract 1
- 101001098560 Homo sapiens Proteinase-activated receptor 2 Proteins 0.000 abstract 1
- 101000713170 Homo sapiens Solute carrier family 52, riboflavin transporter, member 1 Proteins 0.000 abstract 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 102100036863 Solute carrier family 52, riboflavin transporter, member 1 Human genes 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
REFERIDA A UN ANTAGONISTA DEL RECEPTOR 2 ACTIVADO CON PROTEASA (PAR2) TAL COMO UN ANTICUERPO ANTI-PAR2 HUMANO O UN FRAGMENTO DE UN ANTICUERPO QUE SE UNE AL ANTIGENO. DICHO ANTAGONISTA PAR2 PUEDE COMBINARSE CON OTRO AGENTE TERAPEUTICO TAL COMO UN INHIBIDOR DE CITOCINA, UN INHIBIDOR DE NGF, UNA COLCHICINA, UN CORTICOESTEROIDE, ENTRE OTROS. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DEL DOLOR INFLAMATORIO, POSTOPERATORIO, NEUROPATICO, POR FRACTURA, POR FRACTURA OSTEOPOROTICA, POR CANCER O DOLOR ARTICULAR POR GOTA
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3790808P | 2008-03-19 | 2008-03-19 | |
| US11915508P | 2008-12-02 | 2008-12-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20091693A1 true PE20091693A1 (es) | 2009-11-16 |
Family
ID=40718925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2009000397A PE20091693A1 (es) | 2008-03-19 | 2009-03-17 | Antagonista del receptor 2 activado con proteasa |
Country Status (6)
| Country | Link |
|---|---|
| AR (1) | AR070911A1 (es) |
| CL (1) | CL2009000660A1 (es) |
| PE (1) | PE20091693A1 (es) |
| TW (1) | TW201002345A (es) |
| UY (1) | UY31723A (es) |
| WO (1) | WO2009117481A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7214655B2 (en) * | 2001-05-21 | 2007-05-08 | Johnson & Johnson Consumer Companies, Inc. | Peptides and the use thereof in darkening the skin |
| US7888482B2 (en) | 2006-02-10 | 2011-02-15 | Amgen Inc. | Antibodies that bind PAR-2 |
| JO3246B1 (ar) | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
| US9333152B2 (en) | 2011-11-04 | 2016-05-10 | Lipotec, S.A. | Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions |
| EP3049418A1 (en) | 2013-09-25 | 2016-08-03 | Vertex Pharmaceuticals Incorporated | Imidazopyridazines useful as inhibitors of the par-2 signaling pathway |
| US20160000791A1 (en) | 2014-07-07 | 2016-01-07 | Mayo Foundation For Medical Education And Research | Par1 modulation to alter myelination |
| US20190298743A1 (en) * | 2016-05-20 | 2019-10-03 | Takeda Pharmaceutical Company Limited | Treatment of pain |
| US20190201454A1 (en) * | 2016-06-23 | 2019-07-04 | Mayo Foundation For Medical Education And Research | Par2 modulation to alter myelination |
| CR20190417A (es) | 2017-03-16 | 2019-12-06 | Medimmune Ltd | Anticuerpos anti-par2 y usos de los mismos referencia cruzada a solicitudes relacionadas |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996023225A1 (en) * | 1995-01-25 | 1996-08-01 | Cor Therapeutics, Inc. | Recombinant c140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor |
| US5629174A (en) * | 1993-07-26 | 1997-05-13 | Cor Therapeutics, Inc. | Recombinant C140 receptor |
| US20090035315A1 (en) * | 2004-06-17 | 2009-02-05 | Stephan Christgau | Method of Improving Treatments in Rheumatic and Arthritic Diseases |
-
2009
- 2009-03-16 AR ARP090100937A patent/AR070911A1/es unknown
- 2009-03-17 PE PE2009000397A patent/PE20091693A1/es not_active Application Discontinuation
- 2009-03-18 WO PCT/US2009/037504 patent/WO2009117481A1/en not_active Ceased
- 2009-03-18 CL CL2009000660A patent/CL2009000660A1/es unknown
- 2009-03-18 TW TW098108692A patent/TW201002345A/zh unknown
- 2009-03-19 UY UY0001031723A patent/UY31723A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2009000660A1 (es) | 2010-04-16 |
| AR070911A1 (es) | 2010-05-12 |
| TW201002345A (en) | 2010-01-16 |
| WO2009117481A1 (en) | 2009-09-24 |
| UY31723A (es) | 2009-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20091693A1 (es) | Antagonista del receptor 2 activado con proteasa | |
| PE20121563A1 (es) | Anticuerpos que se unen especificamente al receptor epha2 | |
| NI200800284A (es) | Composiciones farmacéuticas de antagonistas del anticuerpo anti-cd40 | |
| MX2012004035A (es) | Anticuerpos neutralizantes anti-ngf humanos como inhibidores selectivos de la trayectoria ngf. | |
| CL2013003214A1 (es) | Formulacion estable que comprende al menos un anticuerpo monoclonal que se une especificamente a pcsk9, un tampon, un surfactante y al menos un estabilizador; y su uso para tratar o prevenir enfermedades relacionadas con el colesterol. | |
| EA200870425A1 (ru) | Применение агонистов рецептора grp119 для повышения костной массы и для лечения остеопороза и связанной с ними комбинированной терапии | |
| NO2017019I1 (no) | Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav | |
| CY1123240T1 (el) | Αντισωμα αντι fgf23 και μια φαρμακευτικη συνθεση που το περιλαμβανει | |
| CL2007002492A1 (es) | Compuestos derivados de bi-,tri o policiclos no aromaticos, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; proceso de preparacion de estos; composicion famaceutica que los comprende; uso en el tratamiento de enfermedades tales como la obesidad, diabetes y dislipidemia, entre otras. | |
| UY32926A (es) | Compuestos como antagonistas de los receptores de ácido lisofosfatídico | |
| BR112017022772A2 (pt) | métodos para tratar ou prevenir cefaleia de enxaqueca | |
| MX2022005330A (es) | Moleculas de union multiespecificas con scfv en el extremo nterminal. | |
| CL2008003694A1 (es) | Compuestos derivados de heterociclo-2-carboxamida sustituida; composicion farmaceutica; combinacion farmaceutica; y su uso como inhibidores de dipeptidil peptidasa iv (dpp-iv) en el tratamiento del asma, epoc y rinitis alergica. | |
| EA201101475A1 (ru) | Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта | |
| EA200870185A1 (ru) | Комбинации ингибиторов ang2 и vegf | |
| NO20092637L (no) | Fremgangsmater for behandling | |
| DOP2009000281A (es) | Moleculas pequeñas que contienen boro | |
| CL2011003147A1 (es) | Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer. | |
| PA8659301A1 (es) | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentracion sanguinea de glp-1 | |
| EA201200204A1 (ru) | Содержащая антитело к her2 композиция для подкожного введения | |
| ECSP10010446A (es) | Uso de ranolazina para el tratamiento del dolor | |
| CL2009000402A1 (es) | Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras. | |
| CL2009000368A1 (es) | 3-(amido o sulfamido)-4-(4-azinil sustituido) benzamidas o benzosulfonamidas; la composicion farmaceutica que los contiene; el uso de los compuestos; y un kit que contiene dichos compeustos; utiles como inhibidores del receptor de quimioquinas cxcr3. | |
| UY30479A1 (es) | Moduladores de benzofuro- y benzotienopirimidina del receptor de histamina h4 | |
| EA201201457A1 (ru) | Органические композиции для лечения заболеваний, связанных с бета-субъединицей эпителиальных натриевых каналов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |